MICS: the European picture

Article

Feature includes: statistics providing a true picture of the number of European surgeons practising MICS; interviews with European experts; why you should adopt the technique; product showcase.

Key Points

So has industry satisfied today's cataract surgeon or does research and development still have some way to go? Naturally, there will always be room for improvement and research will continue to deliver innovative products; however, many do believe that surgeons now have the instruments necessary to allow them to offer patients a truly first-class MICS service. But are the surgeons convinced?

Belgian market intelligence firm, Tools for Growth, set about finding the answer. They assessed European surgeons' attitudes towards MICS, in the hope of finding out how the introduction of these new technologies has influenced the way they actually perform cataract surgery today.

By conducting, what we believe to be, the most comprehensive and insightful independent market research survey ever performed,1 we can now present the true picture of European cataract surgery today.

The market intelligence firm questioned 915 surgeons in France (n=180), Germany (n=200), the UK (n=175), Italy (n=180) and Spain (n=180) at 720 sites across Europe, including public hospitals, private hospitals, eye clinics and private practices between January and February 2008. The distribution of surgeons questioned accurately mirrored the current climate, with approximately one-third of surgeons operating within a public hospital.

Not only were surgeons questioned about their current practice styles, but they were also asked to predict what style of surgery they believe they would be performing in two years' time.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.